0000902664-24-004124.txt : 20240607 0000902664-24-004124.hdr.sgml : 20240607 20240607163117 ACCESSION NUMBER: 0000902664-24-004124 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240605 FILED AS OF DATE: 20240607 DATE AS OF CHANGE: 20240607 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Yi Qingqing CENTRAL INDEX KEY: 0001662556 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37686 FILM NUMBER: 241030073 MAIL ADDRESS: STREET 1: C/O MOURANT OZANNES CORPORATE SERVICES STREET 2: 94 SOLARIS AVENUE CITY: CAMANA BAY, GRAND CAYMAN STATE: E9 ZIP: KY1-1108 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BeiGene, Ltd. CENTRAL INDEX KEY: 0001651308 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 981209416 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: C/O MOURANT GOVERNANCE SERVICES (CAYMAN) STREET 2: 94 SOLARIS AVENUE, CAMANA BAY CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-1108 BUSINESS PHONE: 13459494123 MAIL ADDRESS: STREET 1: C/O MOURANT GOVERNANCE SERVICES (CAYMAN) STREET 2: 94 SOLARIS AVENUE, CAMANA BAY CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-1108 4 1 ownership.xml X0508 4 2024-06-05 0 0001651308 BeiGene, Ltd. BGNE 0001662556 Yi Qingqing OFFICE #122, WINDWARD 3 BUILDING REGATTA OFFICE PARK GEORGE TOWN, GRAND CAYMAN E9 KY1 1103 CAYMAN ISLANDS 1 0 0 0 0 Ordinary Shares 2024-06-05 4 A 0 16341 0 A 45955 D Share Option (Right to Buy) 12.23 2024-06-05 4 A 0 34151 0 A 2034-06-04 Ordinary Shares 34151 34151 D Represents securities underlying restricted share units ("RSUs"). All RSUs will vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each ADS represents 13 ordinary shares. The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. /s/ Qingqing Yi 2024-06-07